Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

706 articles

Research Review

Showing 1–4 of 4 articles · Keyword: Cell membrane Clear keyword

Acta Pharmaceutica Sinica B2022ReviewNon-viral Gene Delivery

1. Cell Membrane-Coated Nanoparticles for Cancer Immunotherapy

Yingping Zeng, Sufen Li, Shufen Zhang, Li Wang, Hong Yuan, Fuqiang Hu

Cancer immunotherapy is limited by tumour heterogeneity, immune cell disability, immunosuppressive tumour microenvironment (TME), and systemic immune toxicity. Cell membrane-coated nanoparticles (CMCNs) offer a biomimetic delivery strategy that inherits source-cell functions—immune evasion, tumour targeting, and…

Read the article

Advanced Functional Materials2021ReviewNon-viral Gene Delivery

2. Cell-Based Delivery Systems: Emerging Carriers for Immunotherapy

Zhaoting Li, Yixin Wang, Yingyue Ding, Lauren Repp, Glen S. Kwon, Quanyin Hu

Immunotherapy has limited response rates and systemic side effects, and synthetic drug delivery systems can be immunogenic and toxic. Cell-based delivery systems—using endogenous cells as natural carriers—offer low immunogenicity, low toxicity, improved biocompatibility, active tissue targeting, and the ability to…

Read the article

Exploration of Medicine2021ReviewNon-viral Gene Delivery

3. Emerging Nanomaterials for Cancer Immunotherapy

Sureshbabu Ram Kumar Pandian, Clayton Fernando Rencllin, Krishnan Sundar

Conventional cancer immunotherapies (checkpoint inhibitors, CAR T cells) are effective but expensive, cause adverse side effects, and face challenges in solid tumours. Nanomaterials offer advantages in delivery, diagnostics, and immune modulation, but a comprehensive understanding of how different nanomaterial types…

Read the article

Theranostics2017ReviewNon-viral Gene Delivery

4. Bioengineering of Artificial Antigen Presenting Cells and Lymphoid Organs

Chao Wang, Wujin Sun, Yanqi Ye, Hunter N. Bomba, Zhen Gu

Immune cell/organ therapies based on manipulation, infusion, and implantation of autologous or allogeneic cells/organs are costly, time-consuming, and sometimes limited in clinical effectiveness. Biomimetic materials and strategies offer an alternative by enabling artificial immune cells and lymphoid organs that are…

Read the article

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.